A World First at the Montreal Heart Institute - Discovery of a personalized therapy for cardiovascular disease

Food and Healthcare Press Releases Tuesday January 13, 2015 16:45
MONTREAL--13 Jan--PRNewswire/InfoQuest
-- Important reduction in events including heart attacks and deaths in patients with the appropriate genetic background to respond to a new medication

Researchers at the Montreal Heart Institute announced today results showing that patients with cardiovascular disease and the appropriate genetic background benefit greatly from the new medication dalcetrapib, with a reduction of 39% in combined clinical outcomes including heart attacks, strokes, unstable angina, coronary revascularizations and cardiovascular deaths. These patients also benefit from a reduction in the amount of atherosclerosis (thickened walls) in their vessels. The detailed results are published in the prestigious Journal Circulation Cardiovascular Genetics. This discovery may also pave the way for a new era in cardiovascular medicine, with personalized or precision drugs.

The team led by Drs Jean-Claude Tardif and Marie-Pierre Dube performed the analysis of 5749 patients who received dalcetrapib or placebo and provided DNA in a clinical study. A strong association was discovered between the effects of dalcetrapib and a specific gene called ADCY9 (adenylate cyclase 9) on chromosome 16, particularly for a specific genetic variant (rs1967309). In patients with the genetic profile AA at rs1967309, there was a 39% reduction in the composite cardiovascular endpoint with dalcetrapib compared to placebo. Supporting evidence was also obtained from a second study, which showed that patients with the favourable genetic profile also benefited from a reduction in the thickness of their carotid artery walls with dalcetrapib.

"These results will lead to a genetics-guided clinical study in patients with the appropriate genetic background to allow review by health regulatory agencies and to provide personalized therapy with dalcetrapib. It also offers great hope for precision treatments for patients with cardiovascular diseases and for curbing atherosclerosis, the first cause of mortality in the world" said lead investigator Jean-Claude Tardif MD, director of the Research Center at the Montreal Heart Institute and professor of medicine at the University of Montreal.

The investigators tested multiple genetic markers across the entire genome in a procedure called genome-wide association study. "We used state-of-the-art genetic and statistical techniques to demonstrate that the effect of the patient's genetic profile was only observed in those treated with dalcetrapib and not placebo. We want to provide patients with additional personalized cardiovascular therapies in the years to come, for more efficacious and safer medicines", commented Marie-Pierre Dube PhD, director of the Beaulieu-Saucier Pharmacogenomics Center at the Montreal Heart Institute and professor of medicine at the University of Montreal.

Dr. Jean-Claude Tardif is available for interviews.
To read the article: http://bit.ly/1tZSSG9
To consult the Journal of the American heart Association website : http://circgenetics.ahajournals.org
Media Invitation :
Wednesday January 14 2015 at 10:30 AM
Auditorium Jean Parisien at the Montreal Heart Institute
5000, Belanger street, Montreal, Quebec H1T 1C8
RSVP : Lise Plante +1-514-376-3330 ext 3898
Dr Jean-Claude Tardif will present the study highlights.
Dr Jean-Claude Tardif
https://www.icm-mhi.org/en/research/researchers/493-jean-claude-tardif
Dre Marie-Pierre Dube
https://www.icm-mhi.org/fr/recherche/chercheurs/501-marie-pierre-dube
About the Montreal Heart Institute: www.icm-mhi.org
About the Montreal Heart Institute Foundation: www.icm-mhi.org
Lise Plante MBA, Communications and Marketing Director, Montreal Heart Institute Foundation, Phone: +1-514-376-3330, ext. 3898, lise.plante@icm-mhi.org , facebook.com/institutcardiologiemontreal, @ICMtl

Latest Press Release

Ascensia Diabetes Care Highlights the Support That Families Provide for People With Diabetes To Mark World Diabetes Day 2018

Today, Ascensia Diabetes Care, a global leading diabetes care company, launched their campaign for World Diabetes Day 2018 to celebrate the important role of families for people with diabetes. They are publishing 38 online artworks that tell the stories...

Qatar Foundation Ushers in New Era of Healthcare With Official Inauguration of Sidra Medicine

Her Highness Sheikha Moza bint Nasser, Chairperson of Qatar Foundation (QF), today officially inaugurated Sidra Medicine - a brand new, world-leading women's and children's hospital in Qatar. The grand opening reflects the country's broader focus and...

Singapore National Eye Centre, Singapore Eye Research Institute And Johnson Johnson Vision Set Sights On Halting Global Myopia Epidemic

New US$26.35 Million Collaboration Seeks Prevention and Treatment Solutions to Address Rising Burden of Condition The Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI) and Johnson & Johnson Vision today announced a...

TIENS Group Launches Global Expansion Into New Retail

Leading healthcare company, TIENS Group, has announced their global expansion into the new retail market with the opening of a new flagship TIENS Experience Store in China. Located in the TIENS International Health Industrial Park, the new store features...

Medicines We Can Trust Campaign Rallies Mekong Governments and Leaders to Improve Access to Quality Medicines

Cambodian Prime Minister Hun Sen and other leaders from the Greater Mekong Subregion joined hands as part of a global campaign to improve access to quality medicines. The announcement was made during the Phnom Penh Regional Conference on the fight...

Related Topics